Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results

Atara Biotherapeutics (NASDAQ:ATRA) announced its earnings results on Tuesday. The biotechnology company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02), FiscalAI reports. The business had revenue of $1.22 million for the quarter, compared to analysts’ expectations of $0.80 million.

Atara Biotherapeutics Stock Performance

Atara Biotherapeutics stock traded down $0.08 during midday trading on Tuesday, reaching $8.10. The stock had a trading volume of 33,145 shares, compared to its average volume of 556,640. The firm’s fifty day simple moving average is $9.04 and its 200-day simple moving average is $7.78. Atara Biotherapeutics has a 1-year low of $3.92 and a 1-year high of $19.15. The stock has a market capitalization of $81.32 million, a P/E ratio of -6.86 and a beta of 0.28.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ATRA shares. Wall Street Zen upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Weiss Ratings upgraded shares of Atara Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Finally, TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.50.

Insider Buying and Selling at Atara Biotherapeutics

In related news, Director Brian N. Cherry acquired 104,166 shares of the company’s stock in a transaction dated Friday, September 4th. The shares were bought at an average price of $9.60 per share, for a total transaction of $999,993.60. Following the purchase, the director directly owned 166,486 shares in the company, valued at approximately $1,598,265.60. This trade represents a 167.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Anhco Nguyen sold 5,062 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $8.08, for a total transaction of $40,900.96. Following the completion of the transaction, the chief executive officer directly owned 132,775 shares of the company’s stock, valued at $1,072,822. This represents a 3.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 41.20% of the stock is currently owned by insiders.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics is a biopharmaceutical company focused on developing allogeneic T-cell immunotherapies for cancer and serious diseases associated with Epstein-Barr virus (EBV). The company’s platform uses donor-derived, virus-specific T cells that are designed to recognize and eliminate infected or malignant cells without requiring cells to be collected from each individual patient. Atara’s lead product, tabelecleucel, is marketed in the European Union under the brand name Ebvallo. The therapy is approved for certain adults and children with EBV-positive post-transplant lymphoproliferative disease, a rare and potentially life-threatening complication that can occur after organ or stem-cell transplantation.